Cost-effectiveness analysis of preimplantation genetic screening and in vitro fertilization versus expectant management in patients with unexplained recurrent pregnancy loss

Fertility and Sterility
Gayathree MurugappanRuth B Lathi

Abstract

To determine whether in vitro fertilization with preimplantation genetic screening (IVF/PGS) is cost effective compared with expectant management in achieving live birth for patients with unexplained recurrent pregnancy loss (RPL). Decision analytic model comparing costs and clinical outcomes. Academic recurrent pregnancy loss programs. Women with unexplained RPL. IVF/PGS with 24-chromosome screening and expectant management. Cost per live birth. The IVF/PGS strategy had a live-birth rate of 53% and a clinical miscarriage rate of 7%. Expectant management had a live-birth rate of 67% and clinical miscarriage rate of 24%. The IVF/PGS strategy was 100-fold more expensive, costing $45,300 per live birth compared with $418 per live birth with expectant management. In this model, IVF/PGS was not a cost-effective strategy for increasing live birth. Furthermore, the live-birth rate with IVF/PGS needs to be 91% to be cost effective compared with expectant management.

References

Oct 1, 1990·Obstetrical & Gynecological Survey·H J CarpD M Serr
Nov 5, 1999·Human Reproduction·S A BrighamR G Farquharson
Jun 25, 2002·Human Reproduction Update·JohnA Collins
Feb 17, 2007·Clinical Obstetrics and Gynecology·Mary Stephenson, William Kutteh
Aug 30, 2008·Fertility and Sterility·Sharon E MoayeriAlan M Garber
Aug 1, 2009·Fertility and Sterility·Kerri MarquardRuth B Lathi
May 15, 2010·Journal of Health Services Research & Policy·Shuby PuthusseryMaurina Baron
Jun 12, 2012·Fertility and Sterility·Brooke Hodes-WertzSantiago Munné
Jul 28, 2012·Fertility and Sterility·UNKNOWN Practice Committee of the American Society for Reproductive Medicine
Jul 31, 2012·American Journal of Obstetrics and Gynecology·John F MissionAaron B Caughey
Jun 20, 2013·Journal of Applied Genetics·Chiara Donatella ViaggiM Pierluigi
Feb 12, 2014·Seminars in Reproductive Medicine·Lora K Shahine, Ruth B Lathi

❮ Previous
Next ❯

Citations

Sep 20, 2015·Fertility and Sterility·Elias M DahdouhJuan Antonio García-Velasco
Oct 17, 2016·Archives of Gynecology and Obstetrics·Maria Elisabetta Coccia, Francesca Rizzello
Oct 19, 2016·La Revue de médecine interne·A MekinianO Fain
Dec 29, 2016·Journal of Assisted Reproduction and Genetics·Sanaz Ghazal, Pasquale Patrizio
Jan 18, 2019·Clinical Genetics·Alessandra AlteriPaola Viganò
Aug 9, 2019·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Limei ZhangCanquan Zhou
Jan 14, 2020·BJOG : an International Journal of Obstetrics and Gynaecology·K NeumannG Griesinger
Jul 15, 2016·Clinical Obstetrics and Gynecology·Jessica M Page, Robert M Silver
Nov 14, 2018·Journal of Assisted Reproduction and Genetics·J E McLaughlinR D Robinson
Aug 19, 2020·Archives of Gynecology and Obstetrics·Katherine E McDanielAli Ahmady
Jul 28, 2017·Journal of Assisted Reproduction and Genetics·Stephen C CollinsWinifred Mak
Aug 2, 2018·Journal of Assisted Reproduction and Genetics·Randi H GoldmanElizabeth S Ginsburg
Nov 21, 2019·Journal of Clinical Medicine·Michal Kirshenbaum, Raoul Orvieto
Jun 25, 2020·International Journal of Molecular Sciences·Ermanno GrecoPaolo Barillari
Jul 6, 2021·F&S Reports·Maria Facadio AnteroMindy S Christianson
Aug 23, 2021·Current Opinion in Obstetrics & Gynecology·Orestis TsonisStamatina Iliodromiti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.